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Abstract 
Purpose: This project investigates the feasibility of implementation of MRI-only prostate planning in a 
prospective multi-center study. Method and Materials: A two-phase implementation model was utilized 
where centers performed retrospective analysis of MRI-only plans for five patients followed by 
prospective MRI-only planning for subsequent patients. Feasibility was assessed if at least 23/25 patients 
recruited to phase 2 received MRI-only treatment workflow. Whole-pelvic MRI scans (T2 weighted, 
isotropic 1.6 mm voxel 3D sequence) were converted to pseudo-CT using an established atlas-based 
method. Dose plans were generated using MRI contoured anatomy with pseudo-CT for dose calculation. 
A conventional CT scan was acquired subsequent to MRI-only plan approval for quality assurance 
purposes (QA-CT). 3D Gamma evaluation was performed between pseudo-CT calculated plan dose and 
recalculation on QA-CT. Criteria was 2%, 2 mm criteria with 20% low dose threshold. Gold fiducial marker 
positions for image guidance were compared between pseudo-CT and QA-CT scan prior to treatment. 
Results: All 25 patients recruited to phase 2 were treated using the MRI-only workflow. Isocenter dose 
differences between pseudo-CT and QA-CT were −0.04 ± 0.93% (mean ± SD). 3D Gamma dose 
comparison pass-rates were 99.7% ± 0.5% with mean gamma 0.22 ± 0.07. Results were similar for the 
two centers using two different scanners. All gamma comparisons exceeded the 90% pass-rate tolerance 
with a minimum gamma pass-rate of 98.0%. In all cases the gold fiducial markers were correctly identified 
on MRI and the distances of all seeds to centroid were within the tolerance of 1.0 mm of the distances on 
QA-CT (0.07 ± 0.41 mm), with a root-mean-square difference of 0.42 mm. Conclusion: The results support 
the hypothesis that an MRI-only prostate workflow can be implemented safely and accurately with 
appropriate quality assurance methods. 
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Purpose: This project investigates the feasibility of implementation of MRI-only prostate
planning in a prospective multi-center study.
Method and Materials: A two-phase implementation model was utilized where
centers performed retrospective analysis of MRI-only plans for five patients followed
by prospective MRI-only planning for subsequent patients. Feasibility was assessed
if at least 23/25 patients recruited to phase 2 received MRI-only treatment workflow.
Whole-pelvic MRI scans (T2 weighted, isotropic 1.6mm voxel 3D sequence) were
converted to pseudo-CT using an established atlas-based method. Dose plans
were generated using MRI contoured anatomy with pseudo-CT for dose calculation.
A conventional CT scan was acquired subsequent to MRI-only plan approval for
quality assurance purposes (QA-CT). 3D Gamma evaluation was performed between
pseudo-CT calculated plan dose and recalculation on QA-CT. Criteria was 2%, 2mm
criteria with 20% low dose threshold. Gold fiducial marker positions for image guidance
were compared between pseudo-CT and QA-CT scan prior to treatment.
Results: All 25 patients recruited to phase 2 were treated using the MRI-only workflow.
Isocenter dose differences between pseudo-CT and QA-CT were−0.04± 0.93% (mean
± SD). 3D Gamma dose comparison pass-rates were 99.7%± 0.5% with mean gamma
0.22 ± 0.07. Results were similar for the two centers using two different scanners. All
gamma comparisons exceeded the 90% pass-rate tolerance with a minimum gamma
pass-rate of 98.0%. In all cases the gold fiducial markers were correctly identified on
MRI and the distances of all seeds to centroid were within the tolerance of 1.0mm of the
distances on QA-CT (0.07 ± 0.41mm), with a root-mean-square difference of 0.42 mm.
Conclusion: The results support the hypothesis that an MRI-only prostate workflow
can be implemented safely and accurately with appropriate quality assurance methods.
Keywords: MRI-only, synthetic CT, pseudo-CT, MRI-alone, prostate
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INTRODUCTION
The benefit of MRI scanning for prostate radiation therapy
planning is-well established with studies demonstrating lower
inter-observer variation in contours, and smaller contours
than CT with subsequent lower doses to normal tissues
such as the penile bulb (1–3). The use of MRI for prostate
delineation therefore potentially allows for more accurate and
more consistent treatment. Typically for prostate planning as
well as other treatment sites the MRI scans are registered to
CT scans to allow for dose computation using the electron
density or physical density map that is generated from simple
calibration of Hounsfield Units (HU). The registration can
be performed using MRI sequences that visualize implanted
gold fiducial markers or less accurately using prostate soft-
tissue. The MRI scans are often not acquired in the treatment
position and do not encompass the patient external contour. The
major limitation of this approach is that systematic registration
uncertainties can result in the prostate contour from MRI (the
target which is used to generate the high dose region) being
misaligned to the gold fiducial positions on CT which are used
for image guidance. These uncertainties have been estimated
to be up to 2mm in standard deviation which are significant
given the small margins used for modern high dose treatments.
These are systematic targeting uncertainties present for every
treatment fraction.
Recently a new paradigm for treatment planning has emerged
that of MRI-alone or MRI-only planning (4–13). In this
approach the HU map for dose calculation is generated from
one or more MRI sequences that encompass the typical field
of view of a planning CT scan (pseudo/synthetic CT). A
variety of methods have been developed to convert MRI
data to HU including calibration and classification methods
using the MRI voxel values, atlas-based methods that use
deformable image registration, hybrid voxel, and atlas methods
and deep-learning algorithms (convolutional neural networks
and generative adversarial networks) (14, 15). The performance
of these algorithms are similar and meet the requirements
for dose calculation accuracy. Clinical acceptance is assessed
by comparison of dose calculation on CT and pseudo-CT for
individual patients. The increase in dose calculation uncertainty
is regarded as a worthwhile trade-off to eliminate the systematic
registration uncertainty (4).
While there have been many investigations performed
retrospectively comparing new pseudo-CT methods to CT
dose calculations, there has been less attention to clinical
implementation of MRI-only workflows and in particular how
these can be performed and assessed to ensure safe clinical
use. Tyagi et al. presented a clinical workflow for MRI-
only simulation (16). Their workflow included an initial CT
simulation appointment where orthogonal x-ray scout images
were used to determine patient dimensions and acceptance for
use by the commercial MRCAT synthetic CT software. If the
patient had prior brachytherapy a small field-of-view CT scan
was acquired to distinguish brachytherapy seeds from fiducial
markers. Forty-two patients from an initial cohort of 48 received
this workflow. Tenhunen et al. presented their experience with
TABLE 1 | Patient details.
Patient detail Mean [range]
Age (years) 73.4 [58–83]
Gleason score 3 + 3 = 6 (n = 3), 3 + 4 = 7 (n = 13), 4 + 3 = 7 (n =
10), 4 + 4 = 8 (n = 1), 4 + 5 = 9 (n = 3)
Pre-treatment PSA 9.0 [0.88–33.8]
Weight (kg) 84.4 [62–122]
Body mass index (BMI) 28.5 [19–39]
MRI-only prostate planning for a large cohort at Helsinki
hospital (17). They found that 92% of patients were suitable
for MRI-only workflow. To date these reports are for single
institution studies.
MRI-only treatment planning is an entirely new approach
for treatment centers and does entail potential risks. Recently a
failuremodes and effects analysis (FMEA) ofMRI-only treatment
planning was reported which demonstrated multiple failure
modes that need to be considered (18). To gain benefit from
these techniques it is important that MRI-only workflows be
implemented in a rigorous and safe manner with appropriate
quality assurance methods. In this work a multi-center study
was initiated for the implementation of an MRI-only prostate
workflow. Two different treatment centers participated and 30
patients in total were recruited, 15 at each center. The study was
designed to enable and assess safe implementation of this new
technique for radiation therapy departments.
METHODS AND MATERIALS
Patients
Thirty patients receiving radical radiation oncology treatment
for prostate cancer were recruited across two treatment centers.
The study title was High precision Prostate Substitute CT based
External beam Radiotherapy (HIPSTER). The study was ethically
approved by the Hunter New England Human Research Ethics
Committee (HREC Registration No: 16/07/20/3.01, NSW HREC
Reference No: HREC/16/HNE/298, Australian New Zealand
Clinical Trials Registry ACTRN12616001653459) and informed
consent was obtained from all patients. The study opened for
recruitment 6 April 2017 and closed to recruitment 16 April 2019
with 15 patients recruited at each center. Eligibility criteria were
men >18 years, low, intermediate or high risk prostate cancer,
fiducial gold markers inserted and prostate or prostate and
seminal vesicle irradiation. The exclusion criteria were inability
to undergo MRI scanning, prior pelvic radiation therapy, unsafe
for or refusal to undergo fiducial marker insertion, presence
of hip prostheses, men highly dependent on medical care or
men with mental or intellectual impairment that would have
difficulty giving informed consent to the study. Patient details
are listed in Table 1. Three fiducial markers were implanted
at least 1 week prior to MRI scanning. Treatment details are
listed in Table 2. Patients were scanned and treated according to
local guidelines except for the MRI-only planning requirements
outlined below.
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TABLE 2 | Details of the centers equipment and techniques.
Center 1 Center 2
CT scanner Toshiba Acquilion or GE LightSpeed-RT or Siemens Confidence Philips Brilliance Big Bore
MRI scanner Siemens Magnetom Skyra 3T Siemens Magnetom Skyra 3T
Treatment planning system Varian Eclipse Philips Pinnacle
Record and verify system Varian Aria Elekta Mosaiq
Linear accelerators Varian Clinac or Truebeam Elekta Synergy (Agility MLC) or Versa
Fiducial markers 1.0 × 3.0mm gold 1.2 × 3.0mm gold
Treatment technique 7-field IMRT (n = 11) 2-arc VMAT (n = 4) 1-arc VMAT (n = 12)
2-arc VMAT (n = 3)
Prescribed dose 60Gy in 20 fractions (n = 14)
78Gy in 39 fractions (n = 1)
60Gy in 20 fractions (n = 9)
78Gy in 39 fractions (n = 6)
Beam energy 6MV (n = 13)
10MV (n = 2)
6 MV
FIGURE 1 | Phase 1 design for retrospective analysis.
Centers and Equipment
While the centers had the same make and model of 3T MRI
scanner (MAGNETOM Skyra, Siemens Healthineers, Erlangen,
Germany) they differed in all other radiation therapy equipment.
Both MRI scanners were fully equipped as MRI simulators with
radiation therapy flat couch tops (CIVCO Medical Solutions,
Coralville, USA), laser bridges (LAP Laser, Luneburg, Germany)
and pelvic coil bridges (CIVCO). Both scanners had regular
quality assurance procedures for image quality and distortion.
Study Design
The study was designed as a two-phase implementation model
where centers performed retrospective analysis of MRI-only
plans for five patients followed by prospectiveMRI-only planning
for subsequent patients. The first phase is commensurate with
literature studies to determine the accuracy of the pseudo-
CT generation (Figure 1). The second phase is designed as a
transition to MRI-only planning without CT where the MRI-
only workflow is implemented but with final quality assurance
to ensure accuracy and safety provided by comparison to CT
scanning. In this phase the CT scan (QA-CT) is only imported
into the TPS following preliminary radiation oncologist approval
of the MRI-only plan (Figure 2). The study aimed to recruit and
treat 25 patients with phase 2 MRI-only prospective planning. As
center 1 had previously performed retrospective analysis for 39
patients (19) they began at phase 2. Center 1 recruited 15 patients
to phase 2 while center 2 recruited five patients to phase 1 and a
further 10 patients to phase 2.
The major endpoint of the study was feasibility of MRI-
only implementation with the aim achieved if >90%
of patients received MRI-only treatment. This allowed
for 2/25 patients to have their MRI-only plans deemed
unacceptable. From previous experience 39/39 patients would
have achieved the dose calculation criteria therefore a 25
patient sample size was regarded as reasonable to recruit
and to demonstrate feasibility. Secondary endpoints were
the assessment of the dose and image-guidance quality
assurance metrics.
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FIGURE 2 | Phase 2 study design for prospective MRI-only planning.
FIGURE 3 | Example patient setup for MRI simulation.
MRI Simulation
The patients were setup in exactly the same position as for
treatment with a radiation therapist in attendance for patient
setup. Patients were aligned using the lasers and MRI visible skin
markers (Liquimark, Suremark) were placed on the patient’s skin
along with temporary tattoo marks. The coil mount was placed
over the patient’s pelvis, without compressing their contour. All
patients were positioned head-first supine and had full bladder
and empty rectum. An example of patient positioning for MRI
simulation is shown in Figure 3.
TABLE 3 | Details of the MRI scans acquired and their function for MRI-only
planning.
Scan type Function
Small field-of view T2 TSE Prostate delineation (CTV) and urethral
delineation
Small field-of-view T1 GRE Flip 80 Fiducial marker delineation
Large field-of-view T2 SPACE Organ delineation
Generation of pseudo- CT
Pseudo-CT Dose calculation
Image guidance using fiducial marker
contours transferred from T1 flip 80
A large field of view 3D sequence was utilized for pseudo-
CT generation. Both centers used the same T2-weighted SPACE
isotropic 3D sequence with 1.6mm voxel side dimensions
and scanning parameters as previously reported (19). The
manufacturers 3D distortion correction was used for all scans.
Routine sequences used at each center were also acquired
for prostate contouring and fiducial marker visualization. These
were not altered for this study as the aim was to follow the
conventional workflow as closely as possible but with MRI
replacing the functionality of CT for treatment dose calculation,
contouring and image-guidance. Details of these sequences have
been reported earlier (19). The functionality of the three main
sequences acquired along with the pseudo-CT are shown in
Table 3. A checklist was designed to ensure adequate MRI
scanning for treatment planning shown in Table 4.
Pseudo-CT Generation
Details of the pseudo-CT method have been reported in detail
previously (19). The method is a hybrid atlas-voxel method using
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an atlas of 39 previously acquired patients. The LFOV SPACE
sequence was de-identified and the patient details replaced with
a study ID before cloud upload to a secure site. The pseudo-CT
was generated and downloaded to the treatment center where
the patient ID and details were entered into the DICOM header
of the scan, replacing the study ID. For the first eight patients
the pseudo-CT generation was identical to the method described
in Dowling et al. (19) including the addition of an extra 1.0mm
“skin” expansion due to the lack of visibility of this layer on MRI.
However, this was discontinued due to erroneous generation of
this layer for patient number 9 of the study and it was decided
that it was clinically more robust to subsequently exclude this
additional layer calculation from the algorithm.
CT Scanning
All patients received CT scans (QA-CT) for quality assurance and
analysis of the MRI-only workflow performed as close as possible
in time as the MRI scan and preferably after the MRI scan.
TABLE 4 | MRI simulation checklist.
MRI skin markers placed on tattoos, patient level with
lasers (scanned HFS)

LFOV MRI acquired first 
LFOV MRI—skin markers visible on LFOV MRI and
patient is leveled (within 0.5 cm)

LFOV MRI—covers external body contour in all
directions and inferior superior extent according to CT
scanning guidelines

LFOV MRI—T2 SPACE, 1.6mm isotropic voxels 
LFOV MRI—3D distortion correction is active 
SFOV T2 TSE—3D distortion correction is active 
SFOV T1 GRE flip80—three gold markers are visible on
the scan, 2D distortion correction is active

Slice thickness was 2.0mm or 2.5mm at Center 1 and 2.0mm
at Center 2.
MRI-Only Treatment Planning
The MRI sequences along with the pseudo-CT were imported
into the treatment planning system (TPS). Alignment of all
scans was visually checked by a radiation therapist. Following
prostate, organ and fiducial marker delineation these contours
were transferred to the pseudo-CT for treatment plan generation
following incorporation of a couch-model. Imbedding of
fiducials into the pseudo-CT scan pixel values was not used.
Treatment plans were then defined according to routine
department protocols. The pseudo-CT with attached fiducial
marker contours was then transferred to the linear accelerator
for image guidance with either cone-beam CT based image
registration to pseudo-CT based on the markers or orthogonal
kilovoltage x-ray image based image registration to digitally
reconstructed radiographs generated from pseudo-CT.
Quality Assurance
A quality assurance procedure was designed for assessment
of MRI-only treatment plans prior to acceptance of the plan
for treatment. This included verification that the scans were
consistent, pseudo-CT appearance and field-of-view, seeds were
correctly identified, and dose and image-guidance metrics as
described below (Table 5). This procedure is designed for an
implementation phase for MRI-only planning where a MRI-only
workflow is used but a gold-standard CT scan is still acquired for
final verification before MRI-only plan is used for treatment.
Following full preparation of the MRI-only treatment plan
and preliminary radiation oncologist approval, the QA-CT scan
was imported into the TPS. This scan was registered to the
pseudo-CT using automatic registration and the MRI plan
transferred to the QA-CT. Dose was recalculated on the QA-
CT using the same fluences and monitor units as the MRI
TABLE 5 | Quality assurance checklist for MRI-only plan.
Distortion correction Confirm that 3D distortion correction was activated for the whole-pelvic scan. Check
distortion corrections for other scans.

Image transfer Confirm that pseudo-CT corresponds to the MRI scan and conventional CT scan to verify




Confirm that pseudo-CT is correctly oriented by comparison to conventional CT scan.
Visually inspect the entire pseudo-CT volume and compare to conventional CT for any
missing tissue or major differences.

Field of view Ensure that the pseudo-CT has sufficient field-of-view to cover all external contours and




Verify that the fiducial marker structures generated on the pseudo-CT correspond to the
fiducial markers determined from the conventional CT (i.e., all fiducial marker locations
have been correctly identified).

Femoral heads Confirm visually that MRI generated bone contours visually correspond to CT bone
contours.

Dose at isocenter Verify that isocenter dose on pseudo-CT is within 2% of conventional CT 
Dose distribution Verify that 3D Gamma comparison at 2%, 2mm criteria > 90% pass-rate for the entire




Verify that fiducial marker contours on pseudo-CT are within 1mm from centroid of the
locations on conventional CT from centroid (accounting for prostate rotation).

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FIGURE 4 | Example of a patient (top-left) large-field-of-view MRI scan; (top-right) dose plan developed on pseudo-CT; (bottom-left) dose recalculated on QA-CT
scan; (bottom-right) gamma analysis result at 2%, 2 mm criteria.
plan. Following alignment using the isocenters the doses were
interpolated onto a 1.5mm voxel size and compared with a
three-dimensional gamma calculation. A 20mm region close
to the skin was excluded from the comparison using a two-
dimensional erosion operation on each axial plane to avoid
the large dose discrepancies due to differences in the external
body contour at CT and MRI. A dose threshold of 20% of the
maximum dose was used and gamma criteria of 3%, 3mm, 2%,
2mm, and 2%, 1mm with the QA-CT as the reference dose
for the comparison. Doses at the isocenter were also compared.
Acceptance criteria for the dose calculation on pseudo-CT were
isocenter dose within 2% and gamma pass-rate > 90% at 2%, 2
mm criteria.
Locations of fiducial markers as identified on MRI were also
compared to locations on the QA-CT scan. The x, y, and z
locations of the markers were carefully measured on the scans
and entered into an Excel spreadsheet which calculated the
centroid of the markers for each scan. The distances of each
marker to the centroid were calculated and compared for the
scans. If all distances were within 1.0mm then the MRI locations
were accepted.
RESULTS
The primary outcome of the study was achieved with all 25
patients in phase 2 having their MRI-only plans accepted by the
radiation oncologist and passing all quality assurance criteria.
These patients were all treated using the MRI-only workflow.
Figure 4 shows an example patient MRI scan, pseudo-CT dose
calculation, and QA-CT dose recalculated for comparison.
For the secondary endpoints all 30 patient results were
assessed including the five patients for phase 1 at center 2 as
the assessment methodology is the same as phase 2. The results
for the ratio of isocenter dose on pseudo-CT and QA-CT are
shown in Figure 5 along with the Bland-Altman levels. The
mean difference in isocenter doses was −0.04% with a standard
deviation of 0.93%. The effect of the first eight patients calculated
with the 1.0mm skin expansion can be seen with lower pseudo-
CT doses. The mean difference for the first eight patients was
−0.64% (0.90%) while for the subsequent patients it was 0.17%
(0.85%). All isocenter dose differences were within 2.0% and only
3 (10%) had more than 1.5% difference.
The results for the gamma evaluations of the dose on pseudo-
CT and QA-CT are shown in Table 6 for the three gamma
criteria. The average gamma pass-rates and the average of the
mean gamma values for all patients are shown.
The results for the comparison of fiducial marker distances
to centroid on MRI and QA-CT are shown in Figure 6. The
average difference between MRI and QA-CT was 0.07mm (1 SD
= 0.41mm) and the root-mean-square difference was 0.42mm.
The maximum difference was 1.00 mm.
DISCUSSION
This study demonstrates that MRI-only workflows can be
implemented in a multi-center setting with appropriate quality
assurance measures to ensure accurate and safe treatment. The
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FIGURE 5 | Isocenter dose comparison on MRI only pseudo-CT scan and QA-CT scan.
TABLE 6 | Results of gamma analysis for comparison of dose calculation using
pseudo-CT and CT.
3%, 3 mm 2%, 2 mm 2%, 1 mm
Gamma pass-rate (%) 100.0 99.7 99.2
Standard deviation (%) 0.1 0.5 1.0
Mean gamma 0.145 0.218 0.221
Standard deviation 0.05 0.07 0.07
study is distinct from most other reported studies in that it is
prospective and the 25 patients received an MRI-only workflow
and treatment.
The QA-CT scan was only used for quality assurance purposes
and this was imported following full generation and preliminary
approval of the MRI only plan. This ensures that an MRI-
only planning workflow is fully implemented but also allows for
verification against the gold standard for dose calculation and
image-guidance. This prepares the center for MRI-only workflow
and ensures safe practice. Subsequent to this implementation
phase the center could then use the MRI-only workflow without
CT acquisition. There are two major potential approaches to
this; consider that there is now adequate confidence in the
process that no specific quality assurance techniques are required;
or to utilize separate quality assurance techniques, and these
decisions will be center-dependent. To provide a method for the
latter approach, in parallel with this study a simple bulk-density
calculation method was developed to compare to the pseudo-CT
dose calculation. This was based on MRI bone and body contour
anatomy and the results will be reported separately. This method
can provide confidence in the integrity of the pseudo-CT and is
robust and easy to perform.
Quality assurance methods to validate fiducial marker
positions as identified on MRI scans would also be beneficial.
FIGURE 6 | Histogram of the differences in distance on MRI and QA-CT of
each marker to the centroid of the markers.
Prostate calcifications can in some cases be difficult to
differentiate from fiducial markers in the sequences used
here. Although potentially problematic this misidentification is
unlikely to lead to image guidance errors as the seed positions
are clearly identified with cone-beam CT scans or x-ray images
prior to treatment and misidentified seed positions are obvious
and can be corrected. However, this is not an ideal scenario as
it could delay treatment. Several methods have been proposed
to ensure fiducial marker identification using MRI techniques or
planar x-ray imaging (16, 20–25).
Patient movement between and during MRI scans is also a
potential source of error in MRI-only planning as the scans
can take several minutes to acquire. It is critical to ensure
that movement has not occurred between the small field-of-
view acquisitions used for CTV definition and fiducial marker
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delineation. If there is a shift of position between them this will
introduce a systematic error in dose delivery to the CTV/PTV.
Visual inspection of alignment of the prostate contour on the
two sequences should be performed. Note that this is not a
problem specific to MRI-only planning. This problem also exists
for MRI-CT registration based treatment planning as is currently
performed. Movement of the patient for the large-field-of-view
MRI scan is not as critical for dose calculation but it will result
in systematic errors of normal tissues that are delineated on this
scan and hence potential mismatch of planned and delivered
doses to these organs.
For patient 9 an error in the pseudo-CT scan was detected
visually during plan generation. This was due to the algorithm
component that introduces an additional “skin” expansion to
compensate for the lack of visibility of the skin onMRI. Although
this correction was introduced in earlier method development
to improve dose calculation accuracy it was felt that it would
be clinically safer to exclude this additional layer for this and
subsequent patients. This patients pseudo-CT was recalculated
with the modified algorithm which generated a new pseudo-CT
that was used for the treatment plan. This has a small effect on
the dose calculation when compared to QA-CT. The patients
prior to patient 9 that included this layer had on average slightly
lower dose calculation on pseudo-CT compared to CT whereas
the patients subsequent to the change had on average slightly
higher dose on pseudo-CT when compared to CT. The patients
prior to the change could be recalculated with the modified
algorithm however the patient plans were developed using the
prior algorithm so this would not reflect the reality for this
prospective study.
CONCLUSION
An MRI-only workflow was introduced in a prospective multi-
center trial setting and all recruited (25 patients) received
the MRI-only workflow. MRI-only planning workflow can be
implemented in a safe manner with appropriate testing and
quality assurance.
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